These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1023 related articles for article (PubMed ID: 20628145)

  • 1. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
    Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
    Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
    Savage KJ; Monti S; Kutok JL; Cattoretti G; Neuberg D; De Leval L; Kurtin P; Dal Cin P; Ladd C; Feuerhake F; Aguiar RC; Li S; Salles G; Berger F; Jing W; Pinkus GS; Habermann T; Dalla-Favera R; Harris NL; Aster JC; Golub TR; Shipp MA
    Blood; 2003 Dec; 102(12):3871-9. PubMed ID: 12933571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
    Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA
    Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
    Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
    Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
    Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ
    Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
    Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
    Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
    Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
    Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
    Feuerhake F; Kutok JL; Monti S; Chen W; LaCasce AS; Cattoretti G; Kurtin P; Pinkus GS; de Leval L; Harris NL; Savage KJ; Neuberg D; Habermann TM; Dalla-Favera R; Golub TR; Aster JC; Shipp MA
    Blood; 2005 Aug; 106(4):1392-9. PubMed ID: 15870177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.